Cabozantinib achieved a nonsignificant overall survival as ramucirumab but significantly prolonged PFS (5.5 [4.6-7.4] months vs. 2.8 [2.7-4.1] months; p = 0.016) in HCC patients with serum alpha-fetoprotein over 400 ng/mL. This evidence concerns the gene AFP and hepatocellular carcinoma.